Terapia endocrina para la prevención primaria del cáncer de seno: Revisión sistemática y metaanálisis actualizado

Autores/as

DOI:

https://doi.org/10.30944/20117582.1095

Palabras clave:

metaanálisis, neoplasias de la mama, prevención & control, prevención primaria, moduladores selectivos de los receptores de estrógeno, inhibidores de la aromatasa

Resumen

Introducción. Debido a que el cáncer de seno es una enfermedad asociada a una significativa tasa de morbilidad y mortalidad cuando se diagnostica en el período sintomático, se han hecho enormes esfuerzos orientados hacia la prevención primaria de esta enfermedad.

Métodos. Se realizó una búsqueda de todos los experimentos clínicos aleatorizados que evaluaran la eficacia de la terapia endocrina para la reducción del riesgo de desarrollar cáncer de seno. La calidad metodológica de los estudios seleccionados fue valorada utilizando la herramienta de la Colaboración Cochrane para medir el riesgo de sesgo en ensayos aleatorizados. Se evaluó la heterogeneidad de los estudios primarios elegibles utilizando los estadísticos T², I², H². El sesgo de publicación fue evaluado mediante el test de Harbord y mediante la gráfica de funnel plot. La medida de efecto utilizada en este metaanálisis fue el riesgo relativo (RR) con el cálculo de los intervalos de confianza (IC) del 95%.

Resultados. Encontramos doce experimentos clínicos aleatorizados que reclutaron a 68.180 mujeres, las cuales fueron asignadas al azar para recibir algún tipo terapia endocrina para reducir el riesgo de desarrollar cáncer de seno o placebo. La terapia endocrina en conjunto redujo el riesgo proporcional de cáncer de seno (invasivo más in situ) en un 42 %, resultado estadísticamente significativo RR 0,58 (IC95% 0,50 – 0,69).

Conclusiones. La terapia endocrina es el manejo estándar de prevención en mujeres sanas con riesgo de desarrollar cáncer de seno no hereditario.

Descargas

Los datos de descargas todavía no están disponibles.

Biografía del autor/a

Eduardo de Jesús Torregroza-Diazgranados, Clínica de Cirugía de Mama, Bogotá, D.C., Colombia.

Médico, especialista en Cirugía general y subespecialista en Cirugía de Mama y Tejidos blandos.

Juan Pablo Torregroza-Castilla, Universidad del Rosario, Bogotá, D.C., Colombia.

Estudiante de Medicina.

Referencias bibliográficas

Toniolo PG, Levitz M, Zeleniuch-Jacquotte A, Banerjee S, Koenig KL, Shore RE, et al. A prospective study of endogenous estrogens and breast cancer in postmenopausal women. J Natl Cancer Inst. 1995;87:190-7. https://doi.org/10.1093/jnci/87.3.190

Santen RJ, Yue W, Naftolin F, Mor G, Berstein L. The potential of aromatase inhibitors in breast cancer prevention. Endocr Rel Cancer. 1999;6:235-43. https://doi.org/10.1677/erc.0.0060235

Simpson ER, Zhao Y, Agarwal VR, Michael MD, Bulun SE, Hinshelwood MM, et al. Aromatase expression in health and disease. Rec Prog Hormone Res. 1997;52:185–213.

Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration; 2011. Disponible en: https://www.cochranehandbook.org/

Tricco AC, Tetzlaff J, Moher D. The art and science of knowledge synthesis. J Clin Epidemiol. 2011;64:11-20. https://doi.org/10.1016/j.jclinepi.2009.11.007

Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomized trials. BMJ. 2011;343:d5928. https://doi.org/10.1136/bmj.d5928

Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stats Med. 2002;21:1539-58. https://doi.org/10.1002/sim.1186

Galbraith RF. Graphical display of estimates having differing standard errors. Technometrics. 1998;30:271- 81. https://doi.org/10.2307/1270081

L’Abbé KA, Detsky AS, O’Rourke K. Meta-analysis in clinical research. Ann Intern Med. 1987;107:224-33. https://doi.org/10.7326/0003-4819-107-2-224

Harbord RM, Egger M, Sterne JAC. Modified test for small-study efects in meta-analyses of controlled trials with binary endpoints. Statist Med. 2006;25:3443-57. https://doi.org/10.1002/sim.2380

Sterne JAC, Egger M. Funnel plots for detecting bias in meta-analysis: Guidelines on choice of axis. J Clin Epidemiol. 2001;54:1046-55. https://doi.org/10.1016/s0895-4356(01)00377-8

Bolaños-Díaz R, Calderón-Cahua M. Introducción al meta-análisis tradicional. Rev Gastroenterol Peru. 2014;34:45-51.

Page MJ, McKenzie JE, Bossuyt PM, Hoffmann TC, Mulrow CD, Shamseer L, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https://doi.org/10.1136/bmj.n71

Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S, Boyle P. Overview of the main outcomes in breast-cancer prevention trials. Lancet. 2003;361:296- 300. https://doi.org/10.1016/S0140-6736(03)12342-2

Cuzick J, Sestak I, Bonanni B, Costantino JP, Cummings S, DeCensi A, et al. Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet. 2013;381:1827-34. https://doi.org/10.1016/S0140-6736(13)60140-3

Mocellin S, Pilati P, Briarava M, Nitti D. Breast cancer chemoprevention: A network meta-analysis of randomized controlled trials. J Natl Cancer Inst. 2016;108:1- 9. https://doi.org/10.1093/jnci/djv318

Mocellin S, Goodwin A, Pasquali S. Risk-reducing medications for primary breast cancer: a network meta-analysis. Cochrane Database Syst Rev. 2019;4:CD012191. https://doi.org/10.1002/14651858.CD012191.pub2

Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial. JAMA. 2006;295:2727–41. https://doi.org/10.1001/jama.295.23.joc60074

Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, et al. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: preventing breast cancer. Cancer Prev Res. 2010;3:696-706. https://doi.org/10.1158/1940-6207.CAPR-10-0076

Decensi A, Robertson C, Guerrieri-Gonzaga A, Serrano D, Cazzaniga M, Mora S, et al. Randomized doubleblind 2 x 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in high-risk premenopausal women. J Clin Oncol. 2009;27:3749-56. https://doi.org/10.1200/JCO.2008.19.3797

Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998;280:2077-82. https://doi.org/10.1001/jama.280.24.2077

Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356:1809-22. https://doi.org/10.1056/NEJMoa067312

Cummings SR, Ettinger B, Delmas PD, Kenemans P, Stathopoulos V, Verweij P, et al. The effects of tibolone in older postmenopausal women. N Engl J Med. 2008;359:697-708. https://doi.org/10.1056/NEJMoa0800743

Cook NR, Lee IM, Zhang SM, Moorthy MV, Buring JE. Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial. Ann Intern Med. 2013;159:77-85. https://doi. org/10.7326/0003-4819-159-2-201307160-00002

Rothwell PM, Price JF, Fowkes FG, Zanchetti A, Roncaglioni MC, Tognoni G, et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet. 2012;379:1602-12. https://doi.org/10.1016/S0140-6736(11)61720-0

Lee IM, Cook NR, Manson JE, Buring JE, Hennekens CH. Beta-carotene supplementation and incidence of cancer and cardiovascular disease: the Women’s Health Study. J Natl Cancer Inst. 1999;91:2102-6. https://doi.org/10.1093/jnci/91.24.2102

Hercberg S, Galan P, Preziosi P, Bertrais S, Mennen L, Malvy D, et al. The SU.VI.MAX Study: a randomized, placebo-controlled trial of the health effects of antioxidant vitamins and minerals. Arch Intern Med. 2004;164:2335-42. https://doi.org/10.1001/archinte.164.21.2335

Avenell A, MacLennan GS, Jenkinson DJ, McPherson GC, McDonald AM, Pant PR, et al. Long-term follow-up for mortality and cancer in a randomized placebo-controlled trial of vitamin D(3) and/or calcium (RECORD trial). J Clin Endocrinol Metab. 2012;97:614-22. https://doi.org/10.1210/jc.2011-1309

Lappe JM, Travers-Gustafson D, Davies KM, Recker RR, Heaney RP. Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am J Clin Nutr. 2007;85:1586-91. https://doi.org/10.1093/ajcn/85.6.1586

Chlebowski RT, Johnson KC, Kooperberg C, Pettinger M, Wactawski-Wende J, Rohan T, et al. Calcium plus vitamin D supplementation and the risk of breast cancer. J Natl Cancer Inst. 2008;100:1581-91. https://doi.org/10.1093/jnci/djn360

Trivedi DP, Doll R, Khaw KT. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. BMJ. 2003;326:469. https://doi.org/10.1136/bmj.326.7387.469

Lee IM, Cook NR, Gaziano JM, Gordon D, Ridker PM, Manson JE, et al. Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women’s Health Study: a randomized controlled trial. JAMA. 2005;294:56-65. https://doi.org/10.1001/jama.294.1.56

Vollset SE, Clarke R, Lewington S, Ebbing M, Halsey J, Lonn E, et al. Effects of folic acid supplementation on overall and site-specific cancer incidence during the randomised trials: meta-analyses of data on 50,000 individuals. Lancet. 2013;381:1029-36. https://doi.org/10.1016/S0140-6736(12)62001-7

Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279:1615-22. https://doi.org/10.1001/jama.279.20.1615

Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335:1001-9. https://doi.org/10.1056/NEJM199610033351401

The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349-57. https://doi.org/10.1056/NEJM199811053391902

ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA. 2002;288:2998-3007. https://doi.org/10.1001/jama.288.23.2998

Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360:1623-30. https://doi.org/10.1016/s0140-6736(02)11600-x

Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7-22. https://doi.org/10.1016/S0140-6736(02)09327-3

Strandberg TE, Pyörälä K, Cook TJ, Wilhelmsen L, Faergeman O, Thorgeirsson G, et al. Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet. 2004;364:771- 7. https://doi.org/10.1016/S0140-6736(04)16936-5

Forbes JF, Sestak I, Howell A, Bonanni B, Bundred N, Levy C, et al. Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double blind, randomised controlled trial. Lancet. 2016;387:866-73. https://doi.org/10.1016/S0140-6736(15)01129-0

Powles TJ, Ashley S, Tidy A, Smith IE, Dowsett M. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst. 2007;99:283-90. https://doi.org/10.1093/jnci/djk050

Cuzick J, Sestak I, Cawthorn S, Hamed H, Holli K, Howell A, et al. Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I cancer prevention trial. Lancet Oncol. 2015;16:67-75. https://doi.org/10.1016/S1470-2045(14)71171-4

Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 2005;97:1652-62. https://doi.org/10.1093/jnci/dji372

Veronesi U, Maisonneuve P, Rotmensz N, Bonanni B, Boyle P, Viale G, et al. Tamoxifen for the prevention of breast cancer: Late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy. J Natl Cancer Inst. 2007;99:727-37. https://doi.org/10.1093/jnci/djk154

Martino S, Cauley JA, Barrett-Connor E, Powles TJ, Mershon J, Disch D, et al. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst. 2004;96:1751-61. https://doi.org/10.1093/jnci/djh319

Publicado

2022-04-04

Cómo citar

(1)
Torregroza-Diazgranados, E. de J.; Torregroza-Castilla, J. P. Terapia Endocrina Para La prevención Primaria Del cáncer De Seno: Revisión sistemática Y metaanálisis Actualizado. Rev Colomb Cir 2022, 37, 377-392.

Número

Sección

Artículo Original